Today: 9 June 2026
Vietnam stocks week ahead: Ho Chi Minh VN-Index faces a settlement test after T+2 glitch

Vietnam stocks week ahead: Ho Chi Minh VN-Index faces a settlement test after T+2 glitch

Ho Chi Minh City, March 1, 2026, 16:19 ICT — The session has ended.

  • HoSE will resume trading on Monday, following a settlement hiccup—some T+2 deliveries were held up late last week due to KRX system maintenance.
  • The VN-Index closed just shy of 1,880 on Friday, lifted by gains in energy and tech stocks; large caps, though, mostly sat out the rally after the Tet holiday.
  • Monday’s manufacturing PMI is first up for traders, followed by a cluster of February macro numbers later in the week.

The Ho Chi Minh Stock Exchange starts the week facing renewed back-office headaches after the securities depository reported a delay in allocating certain securities set for settlement. The holdup followed scheduled IT maintenance performed by the KRX contractor, according to the .

The issue disrupted the T+2 settlement — that’s “trade date plus two business days” — causing a temporary holdup for certain government bonds and equities, brokerage notifications and updates from the depository show. The Investor

The Vietnam Securities Depository and Clearing Corporation managed to finish the delayed settlements later Friday, with brokers telling state media that trading rights came back online around 2:30 p.m.

The VN-Index scraped out a gain on Friday, finishing up just 0.69 point, or 0.04%, at 1,880.33, after tumbling more than 16 points in the early afternoon. Trading value slipped roughly 5%, landing above 30 trillion dong ($1.2 billion). The VN30, tracking HoSE’s largest 30 stocks, dropped 0.39% to 2,061.75.

Oil and gas, tech, and utilities stocks lifted the market, according to VNDIRECT, but insurance and F&B names pulled in the opposite direction. Top index contributors: VIC, BSR, GAS. On the foreign side, net buying reached roughly 190.6 billion dong, with FPT, GMD and MWG attracting the bulk.

Nhi Nguyen at Shinhan Securities said the VN-Index is running up against resistance near 1,900. Friday’s session, she wrote, “looked like a technical shake-out,” with steady cash flow colliding with profit-taking. Nguyen also highlighted fertilizer stocks getting a lift from pricier urea, and noted energy shares did their part to prop up the index.

This week’s data releases kick off with S&P Global’s manufacturing PMI on Monday. Later on, investors will parse February trade, inflation, industrial output, retail sales, and foreign direct investment figures, according to Trading Economics.

Vingroup is looking to bring in as much as $350 million through an international bond offering, giving buyers the right to swap the bonds for shares in Vinpearl, its hospitality unit—a structure the company last tapped in a deal set for late 2025. According to Vingroup, the sale is planned for the second quarter, pending approvals and depending on how markets shape up.

Traders are eyeing whether the post-holiday gains have more room, provided there’s no fresh disruption under the surface. A second settlement delay would be trouble, especially with the index hovering at a critical threshold.

The rally’s breadth has thinned on occasion, with large caps flashing signs of fatigue. If the index stalls near 1,900 again, or if settlement glitches resurface—or weaker February figures come in—banks and consumer names could easily slide back into the red.

Foreign flows remain a key factor. Some stability comes from net buying, especially as locals move to lock in gains, but that support tends to vanish fast once volatility picks up.

Stock Market Today

  • Pro Portfolio Adds Broadcom and Netflix Shares, Upgrades Broadcom Rating
    June 9, 2026, 10:19 AM EDT. The Pro Portfolio is buying 80 shares of Broadcom (AVGO) at around $405, increasing its holdings to 512 shares (3.4% of the portfolio). It is also purchasing 372 shares of Netflix (NFLX) near $82.35, increasing its stake to 2,107 shares (2.85%). Broadcom's AI chip forecast for H2 2026 is viewed as conservative following a $35 billion private credit deal involving Apollo and Blackstone. The rating for Broadcom is upgraded to One, with a checkpoint price of $330 maintained. Netflix's shares are seen as undervalued despite recent declines, supported by a $25 billion buyback and rising U.S. viewership. Netflix's ad business shows growth potential, reaching 250 million monthly active viewers, reinforcing optimism amidst concerns over consumer spending.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
STI flirts with 5,000: Yangzijiang and AEM set the pace on SGX in the week ahead
Previous Story

STI flirts with 5,000: Yangzijiang and AEM set the pace on SGX in the week ahead

Amazon stock in focus after $50 billion OpenAI partnership lands in SEC filing
Next Story

Amazon stock in focus after $50 billion OpenAI partnership lands in SEC filing

Go toTop